Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration ...
Glenmark Therapeutics Inc., USA launches Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC)
Glenmark Therapeutics Inc., USA (Glenmark) is pleased to announce the launch1 of Polyethylene Glycol 3350, Powder for ...
Morningstar2d
Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a research–led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on ...
The Victoria Advocate20d
Glenmark Pharmaceuticals Inc., USA acquires and launches Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials
Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a research–led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on ...
Morningstar12d
Glenmark Therapeutics Inc., USA launches Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC)
MAHWAH, N.J., March 10, 2025 /PRNewswire/ -- Glenmark Therapeutics Inc., USA (Glenmark) is pleased to announce the launch1 of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC ...
Longview News-Journal24d
Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial
Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a research–led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on ...
Eli Lilly (LLY) Leads India’s Weight-Loss Drug Race with Mounjaro
Eli Lilly (LLY) has launched its weight-loss and diabetes drug, Mounjaro (tirzepatide), in India, securing a first-mover ...
Business Line10d
Glenmark expands diabetes portfolio with new Empagliflozin treatments
Glenmark Pharmaceuticals announced today the launch of Empagliflozin and its fixed-drug combinations in India under the brand names Glempa, Glempa-L, and Glempa-M. The shares of Glenmark ...